Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DELW64
|
|||
| Drug Name |
NX-5948
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Chronic lymphocytic leukaemia [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Phase 1 | [1] | |
| Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C82-C85; ICD-9: 200, 202] | Phase 1 | [1] | ||
| Company |
Nurix
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05131022) A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies. U.S.National Institutes of Health. | |||
| REF 2 | The Evolution of Therapies Targeting Bruton Tyrosine Kinase for the Treatment of Chronic Lymphocytic Leukaemia: Future Perspectives. Cancers (Basel). 2023 May 3;15(9):2596. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.